Surgery as a Treatment for Medically Intractable Epilepsy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01273129|
Recruitment Status : Recruiting
First Posted : January 10, 2011
Last Update Posted : October 19, 2020
- Medically intractable epilepsy is the term used to describe epilepsy that cannot be controlled by medication. Many people whose seizures do not respond to medication will respond to surgical treatment, relieving seizures completely or almost completely in one-half to two-thirds of patients who qualify for surgery. The tests and surgery performed as part of this treatment are not experimental, but researchers are interested in training more neurologists and neurosurgeons in epilepsy surgery and care in order to better understand epilepsy and its treatment.
- To use surgery as a treatment for medically intractable epilepsy in children and adults.
- Children and adults at least 8 years of age who have simple or complex partial seizures (seizures that come from one area of the brain) that have not responded to medication, and who are willing to have brain surgery to treat their medically intractable epilepsy.
- Participants will be screened with a medical history, physical examination, and neurological examination. Imaging studies, including magnetic resonance imaging and computer-assisted tomography (CT), may also be conducted as part of the screening. Participants who do not need surgery or whose epilepsy cannot be treated surgically will follow up with a primary care physician or neurologist and will not need to return to the National Institutes of Health for this study.
- Prior to the surgery, participants will have the following procedures to provide information on the correct surgical approach.
- Video electroencephalography monitoring to measure brain activity during normal activities within a 24-hour period. Three to four 15-minute breaks are allowed within this period.
- Wada test to evaluate speech, comprehension, and memory centers of the brain, using a contrast dye to study the blood vessels of the brain and a short-term anesthetic administration procedure to test the effects on areas of speech and memory.
- Depth electrodes and/or brain surface electrodes to measure brain activities and determine the part of the brain that is responsible for the seizures (seizure focus).
- Participants will have a surgical procedure at the site of their seizure focus. Brain lesions, abnormal blood vessels, tumors, infections, or other areas of brain abnormality will be either removed or treated in a way that will stop or help prevent the spread of seizures without affecting irreplaceable brain functions, such as the ability to speak, understand, move, feel, or see.
- Participants will return for outpatient visits and brain imaging studies 2 months, 1 year, and 2 years after surgery.
|Condition or disease||Intervention/treatment||Phase|
|Epilepsy Epilepsy, Temporal Lobe Partial Epilepsy||Procedure: Surgical Treatment of drug resistantepilepsy||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||300 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Surgery as a Treatment for Medically Intractable Epilepsy|
|Actual Study Start Date :||March 21, 2011|
|Estimated Primary Completion Date :||March 1, 2028|
|Estimated Study Completion Date :||March 1, 2028|
Patients undergoing brain surgery to treat drug resistant epilepsy and are enrolled in protocol 11-N-0051 Epilepsy Surgery.
Procedure: Surgical Treatment of drug resistantepilepsy
Removal of mesial temporal sclerosis through anterior temporal lobectomy or selective amygdalohippocamp ectomy. Selective amygdalohippocamp ectomy removes the medial temporal lobe and leaves more of the surrounding normal brain than anterior temporal lobectomy.
- Change in seizure frequency [ Time Frame: 1 year ]Change in seizure frequency, as measured by the Engel scale before and 1 year after treatment.
- Percentage of patients who are able to be completely withdrawn from anti-epileptic medication [ Time Frame: 2 Year ]The proportion of patients who are able to completely withdrawn from anti-epileptic medication (measured 2 years after surgery; subjects will remain on antiepileptic medications for one year after surgery, and may be withdrawn from antiepileptic medications during the second year after surgery).
- Percentage of patients who are seizure-free (Engel Class I) [ Time Frame: 1 Year ]The proportion of patients who are seizure-free (Engel Class I) one year after surgery.
- Mean Engel Class one year after surgery stratified by the type of surgical procedure [ Time Frame: 1 Year ]Mean Engel Class one year after surgery stratified by type of surgical procedure performed.
- Percentage of patients with permanent neurological side effectsfrom surgical treatment [ Time Frame: 1 Year ]Permanent neurological deficits, assessed one year after surgery.
- Neurophysiological correlates of cognitive function [ Time Frame: Baseline ]1. Differences in local field potential (LFP) oscillatory power in both intracranial EEG and microwire recordings among a) the awake resting state, b) during cognitive activity, c) immediately prior to and during seizure activity, and d) during sleep.
- 6. Neurophysiological correlates of human cognitive function and to provide invasive monitoring for patients with tumor related epilepsy [ Time Frame: Baseline and 1 year ]Outcomes for subjects with tumor related epilepsy will be assessed under a separate protocol, 16-N-0041, Tumor Related Epilepsy
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01273129
|Contact: Gretchen C Scott, R.N.||Not Listed||SNBrecruiting@nih.gov|
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) 800-411-1222 ext TTY8664111010 email@example.com|
|Principal Investigator:||Kareem A Zaghloul, M.D.||National Institute of Neurological Disorders and Stroke (NINDS)|